KBC Securities - ArGEN-X SE (ARGX) argenx FIRST LOOK : 3Q23 Results Above and Beyond

Report

KBC Securities

Thomas Vranken

argenx FIRST LOOK : 3Q23 Results Above and Beyond

In line with previous quarters, argenx' again beat consensus estimates for Vyvgart net product sales in 3Q23 to reach $ 329m (KBCSe: $ 291m, CSS: $ 294m). The company is also on track to submit Vyvgart Hytrulo for CIDP in the US by YE23. Timelines are reiterated for pemphigus and SC-ITP as upcoming catalysts toward YE23. We maintain our €495 TP and Buy rating.

31/10/2023 1 EN

Underlying

ArGEN-X SE

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

See profile

NL0010832176 Euronext Brussels Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by approximately 9%, while the share price has rallied by around 40% over the same period, resulting in ...

February 5, 2026 February 5, 2026 1 EN

SmartInsider

Argen X SE: 1 director

A director at Argen X SE sold after exercising options/sold 3,625 shares at 695.710EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing r...

Free Trial

January 15, 2026 January 15, 2026 1 EN

KBC Securities

argenx Vyvgart sBLA acceptance in seronegative gMG comes with priority review

argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 11K patients on top of the 17K addressable population at launch in the US. € 900 TP and BUY maintaine...

January 13, 2026 January 13, 2026 1 EN

Inventiva FIRST LOOK: preliminary FY25 results hold no surprises

Inventiva reported preliminary FY25 results which hold no surprises, and confirmed its cash-runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to middle of 1Q27. This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We reiterate our Buy rating and € 7 TP.

6h / 2m 6h / 2m 1 EN

Guy Sips ... (+3)

Guy Sips
Mathijs Geerts Danau
Wim Hoste

Morning Notes : AGFB BB, DSFIR NA, IVA FP, MDXH BB

: AGFB BB, DSFIR NA, IVA FP, MDXH BB

6h / 55m 6h / 55m 1 EN

Mathijs Geerts Danau

Mathijs Geerts Danau

mdxhealth ExoDx boosts 2026 growth expectations

Following mdxhealth preliminary 2025 full-year sales and 2026 sales guidance in the $ 137-140m range, we update our model and raise 2026 revenue estimates to $ 139.9m, driven by ExoDx and synergy potential with the GPS test. The ExoDx acquisition should ensure the company's high growth profile, and the increased scale should allow for further operational leverage. That said, we note that the company will likely require additional funding to cover cash outflow obligations. Given the high growth outlook and operational leverage potential, we reiterate our BUY and raise our TP to $ 6 from $ 4.2.

7h / 47m 7h / 47m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

argenx FIRST LOOK : 3Q23 Results Above and Beyond

We are a financial services provider for several types of professional clients, each with distinct needs.

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

Argen X SE: 1 director

argenx Vyvgart sBLA acceptance in seronegative gMG comes with priority review

Inventiva FIRST LOOK: preliminary FY25 results hold no surprises

Morning Notes : AGFB BB, DSFIR NA, IVA FP, MDXH BB

mdxhealth ExoDx boosts 2026 growth expectations

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe